Psychedelics Archives - Page 29 of 68

2 minute read

Psychedelic Therapies Soon Available In Australia Via Incannex Healthcare And Subsidiary

May 16, 4:10 PM

Biotech giant Incannex Healthcare Ltd (NASDAQ: IXHL) shared a business presentation of its newly formed psychedelic-assisted therapies subsidiary company, Psychennex Pty Ltd.

IXHL

3 minute read

Psyched: $20M Research Fund, LSD Microdosing For Cancer, MEAI Enters Clinical Stage, Reform Update & More

By Lara Goldstein

May 15, 5:30 PM

Researchers At Johns Hopkins Get $20M Fund Prompted By Longtime Psychedelics Scientist Johns Hopkins University academics received a boost in funding thanks to the recently launched Roland R. Griffiths Ph.D. Professorship Fund.

ATAI

2 minute read

Filament Health’s Q1 2023 Financial Results, Material Uncertainty On The Horizon

By Lara Goldstein

May 15, 2:15 PM

Natural psychedelics drug developer Filament Health Corp. (OTCQB: FLHLF) shared its interim financial results and further business highlights for the first quarter ended March 31, 2023.

FLHLF

4 minute read

EXCLUSIVE: Lessons From Psychedelics Markets Through Business, Legal And Reciprocity Lenses

By Lara Goldstein

May 12, 7:37 PM

This year’s edition of Benzinga’s Psychedelics Capital Conference hosted some of the most knowledgeable panelists and hot-button discussions currently in the space.

BWVI

2 minute read

EXCLUSIVE: Clearmind Medicine Secures Approval To Launch Clinical Trial For Alcohol Addiction Treatment

By Lara Goldstein

May 12, 8:30 AM

Clearmind Medicine Inc.

CMND

1 minute read

FDA Gives Nod To IntelGenx’s Migraine Solution As Revenues Plunge 32%; Q1 Results Report

By Nicolas Jose Rodriguez

May 11, 6:33 PM

IntelGenx Technologies Corp. (OTC: IGXT) reported on Thursday a 32% decrease in total revenues for the first quarter of 2023, amounting to $162,000 as compared to $237,000 in the same

IGXT

1 minute read

New Psilocybin Chocolate Bar By Vertical Cannabis And Psychedelics Company

By Lara Goldstein

May 11, 4:04 PM

Holistic wellness company Kaya Group’s (OTC: NUGL) subsidiary Kaya Extracts is expanding its product offerings with two new psychedelic mushroom chocolates, available in Jamaica's legal psilocybin market.

NUGL

2 minute read

GH Research: Q1 2023 Financials And Businesses For European 5-MeO-DMT Depression Treatment Developer

By Lara Goldstein

May 11, 3:36 PM

GH Research PLC (NASDAQ: GHRS), a Dublin-based clinical-stage biotech company reported financial results for the first quarter ended March 31, 2023.

GHRS

2 minute read

COMPASS Pathways Reports Q1 2023: Financials, Commercial Groundwork And Ongoing Phase 3 Trials

By Lara Goldstein

May 11, 3:18 PM

Mental healthcare biotech company advancing psilocybin therapy COMPASS Pathways plc (NASDAQ: CMPS) reported its financial results for the first quarter 2023 ended March 31, 2023 and updated on recent business and clinical progresses. In numbers:

CMPS

1 minute read

Optimi Health Boosts Psilocybin Production With New Health Canada License And Supply Deal

By Lara Goldstein

May 11, 2:42 PM

Psychedelics research and manufacturing company Optimi Health Corp. (OTCQX: OPTHF) received a “Natural Health Product Site" license, adding to its existing permits to produce and supply psychedelic substances including MDMA and psilocybin.

OPTHF